Skip to main content
    P

    PolyPid (PYPD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.15
    -0.11 (-1.76%)

    Market Cap: $132.25M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    PolyPid (PYPD) Earnings: Report Dates and Results

    Updated Nov 11, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    PolyPid (PYPD) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, PolyPid reported EPS of -$0.24, below the $0.46 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    67%(18/27)
    Avg Surprise
    -1.87%

    Upcoming Estimates

    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.41
    Range-$0.55 - -$0.30
    7 analysts
    Revenue Consensus
    N/A
    RangeN/A
    7 analysts

    Next Report

    PYPD has an expected report date of Feb 9, 2027.

    PYPD Earnings Call

    The latest PYPD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 27 quarters below that had an estimate, PYPD beat 18 and missed 9. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 152.17% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.24$0.46N/A-152.17%MissN/A31 up, 0 downNov 11, 2026
    Jun 30, 2026-$0.35-$0.34-$0.49 - -$0.32-2.94%MissN/A41 up, 1 downAug 12, 2026
    Mar 31, 2026-$0.35-$0.43-$0.49 - -$0.37+18.60%BeatN/A30 up, 1 downMay 13, 2026
    Dec 31, 2025-$0.41-$0.33-$0.38 - -$0.30-24.24%MissN/A43 up, 1 downFeb 11, 2026
    Sep 30, 2025-$0.37-$0.52-$0.69 - -$0.39+28.85%BeatN/A40 up, 2 downNov 12, 2025
    Jun 30, 2025-$0.78-$0.55-$0.70 - -$0.41-41.82%MissN/A4N/AAug 13, 2025
    Mar 31, 2025-$0.70-$0.82-$0.84 - -$0.80+14.63%BeatN/A20 up, 0 downMay 14, 2025
    Dec 31, 2024-$1.07-$0.88-$1.04 - -$0.71-21.59%MissN/A4N/AFeb 12, 2025
    Sep 30, 2024-$1.22-$1.00-$1.12 - -$0.88-22.00%MissN/A40 up, 0 downNov 13, 2024
    Jun 30, 2024-$1.25-$1.30-$1.51 - -$1.19+3.85%BeatN/A30 up, 0 downAug 14, 2024
    Mar 31, 2024-$1.37-$1.41-$1.96 - -$1.08+2.84%BeatN/A31 up, 0 downMay 8, 2024
    Dec 31, 2023-$3.84-$4.29-$5.16 - -$2.17+10.49%BeatN/A30 up, 0 downFeb 14, 2024
    Sep 30, 2023-$3.40-$4.43-$5.04 - -$3.62+23.25%BeatN/A31 up, 0 downNov 8, 2023
    Jun 30, 2023-$10.80-$13.32N/A+18.92%BeatN/A20 up, 0 downAug 9, 2023
    Mar 31, 2023-$8.40-$4.80-$12.31 - -$4.80-75.00%MissN/A31 up, 0 downMay 10, 2023
    Dec 31, 2022-$9.60-$12.36-$14.41 - -$10.51+22.33%BeatN/A40 up, 0 downFeb 8, 2023
    Sep 30, 2022-$14.40-$16.22-$17.72 - -$14.71+11.22%BeatN/A41 up, 0 downNov 9, 2022
    Jun 30, 2022-$18.30-$20.10N/A+8.96%BeatN/AN/A0 up, 0 downAug 10, 2022
    Mar 31, 2022-$18.90-$18.92-$20.72 - -$17.72+0.11%BeatN/A60 up, 0 downMay 11, 2022
    Dec 31, 2021-$21.30-$16.64-$19.22 - -$15.32-28.00%MissN/A6N/AFeb 9, 2022
    Sep 30, 2021-$15.90-$18.83-$19.82 - -$17.42+15.56%BeatN/A5N/ANov 10, 2021
    Jun 30, 2021-$16.80-$15.75-$18.02 - -$13.51-6.67%MissN/A5N/AAug 11, 2021
    Mar 31, 2021-$14.10-$15.00-$16.82 - -$13.51+6.00%BeatN/A4N/AMay 12, 2021
    Dec 31, 2020-$12.30-$15.23-$21.92 - -$11.71+19.24%BeatN/A4N/AFeb 10, 2021
    Sep 30, 2020-$10.50-$12.20-$14.41 - -$9.91+13.93%BeatN/A4N/ANov 11, 2020
    Jun 30, 2020-$191.10-$207.21N/A+7.77%BeatN/A4N/AAug 19, 2020
    Mar 31, 2020-$0.33-$12.60N/A+97.42%BeatN/AN/AN/AJun 29, 2020
    Dec 31, 2017-$3.23N/AN/AN/AN/AN/AN/AN/AMar 14, 2018
    Sep 30, 2017-$0.86N/AN/AN/AN/AN/AN/AN/ADec 20, 2017
    Last 29 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.26, after -$4.91 the year before. It was -$4.09 for the year ended Dec 31, 2017, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.26N/A
    Dec 31, 2024-$4.91N/A
    Dec 31, 2023-$26.44N/A
    Dec 31, 2022-$61.20N/A
    Dec 31, 2021-$68.10N/A
    Dec 31, 2020-$214.23N/A
    Dec 31, 2017-$4.09N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,400 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,39310
    2026Q2Jun 30, 20264,8369
    2026Q1Mar 31, 20263,8749
    2025Q4Dec 31, 20254,4089
    2025Q3Sep 30, 20253,8238
    2025Q2Jun 30, 20252,9987
    2025Q1Mar 31, 20253,7467
    2024Q4Dec 31, 20244,0479

    2026Q3 Earnings Call

    Opening remarks

    Yehuda Leibler Investor Relations Thank you, operator. Thank you all for joining PolyPid's third quarter 2026 earnings conference call. Earlier today, PolyPid released its financial results for the three and nine months ended September 30, 2026. A copy of the press release is available in the investor section of the company's website at www.polypid.com. Joining me on the call today are Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Ori Warshavsky, Chief Operating Officer, U.S., of PolyPid; and Jonny Missulawin, Chief Financial Officer of PolyPid. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities laws. These include statements about the FDA's review of the D-PLEX100 NDA, including labeling discussions, the PDUFA goal date, and the FDA pre-approval inspection. They also cover the potential approval of D-PLEX100 and the anticipated timing of its U.S. commercial launch by Azurity Pharmaceuticals, as well as potential reimbursement for D-PLEX100, including the anticipated timing of a CMS decision on a New Technology Add-on Payment, or NTAP. We will also discuss the potential label expansion of D-PLEX100 and planned communications with the FDA, and the EMA's review of the MAA for D-PLEX100, including the anticipated timing of the decision and a potential U.S. launch. In addition, we will refer to the company's plans for Europe, Canada, and other territories, including potential partnerships and their timing. Finally, these statements include the company's PolyPid 2030 vision and levers for growth, the development plans and anticipated timing for PD01B and PD03A, and the company's expectation that its cash resources will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks described from time to time in the company's filings with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company's filings with the SEC, including its annual report on Form 20-F, filed on February 25, 2026. PolyPid disclaims any intention or obligation, except as required by law, to update or revise any forward-looking statements. This conference call contains time-sensitive information that speaks only as of the live broadcast today, November 11, 2026. With that, it's my pleasure to turn the call over to Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. Dikla?

    Dikla Akselbrad CEO Thank you, Yehuda, and good morning, everyone. We are now just over two weeks from our PDUFA goal date of November 28, and this is a defining moment for PolyPid. Let me start with the FDA review.

    Frequently Asked Questions About PYPD

    When is PolyPid's next earnings date?

    PolyPid's next earnings report is expected for Feb 9, 2027.

    Did PYPD beat earnings estimates last quarter?

    No. PolyPid reported EPS of -$0.24 for the quarter ended Sep 30, 2026, below the $0.46 estimate by 152.17%.

    What EPS do analysts expect from PYPD next quarter?

    The consensus EPS estimate for PolyPid for the quarter ending Dec 31, 2026 is -$0.41 from 7 analysts, with estimates from -$0.55 to -$0.30.

    How often does PYPD beat earnings estimates?

    PolyPid beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -22.59%.